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Abstract
Tumor neo-vascularization is critical for tumor growth, invasion and metastasis, which has been considered to be mediated
by a mechanism of angiogenesis. However, histopathological studies have suggested that tumor cells might be the
progenitor for tumor vasculature. Recently, we have reported that the precancerous stem cells (pCSCs) representing the
early stage of developing cancer stem cells (CSCs), have the potential for both benign and malignant differentiation.
Therefore, we investigated whether pCSCs serve as progenitors for tumor vasculogenesis. Herein, we report that in the
pCSC-derived tumors, most blood vessels were derived from pCSCs. Some pCSCs constitutively expressed vasculogenic
receptor VEGFR-2, which can be up-regulated by hypoxia and angiogenesis-promoting cytokines, such as GM-CSF, Flt3
ligand, and IL-13. The pCSCs are much more potent in tumor vasculogenesis than the differentiated tumor monocytic cells
(TMCs) from the same tumor, which had comparable or even higher capacity to produce some vascular growth factors,
suggesting that the potent tumor vasculogenesis of pCSCs is associated with their intrinsic stem-like property. Consistently
tumor vasculogenesis was also observed in human cancers such as cervical cancer and breast cancer and xenograft
lymphoma. Our studies indicate that pCSCs can serve as tumor vasculogenic stem/progenitor cells (TVPCs), and may explain
why anti-angiogenic cancer therapy trials are facing challenge.
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Introduction
Tumor malignancy is determined by the growth rate,
invasiveness and metastasis of tumor. The growth rate, invasive-
ness and outcome of metastasis are in turn dependent on the
establishment of tumor vascular network, which provides nutrients
required for cancer cell expansion and drains away wastes
produced by cancer cells [1–5]. The prevailing concept holds
that the tumor vasculature is formed via a mechanism of tumor
angiogenesis: pre-existing blood vessels, which are stimulated by
various angiogenic growth factors secreted by cancer cells, such as
vascular endothelial growth factor (VEGF), angiopoietin (Ang)-1,
and Ang-2, sprout into cancer cell clusters to form tumor
vasculature [1,2]. VEGF binds receptors VEGFR-1 (Flt1) and
VEGFR-2 (KDR/Flk1); and the latter appears to mediate almost
all of the known cellular response to VEGF [6–8]. While the
existence of tumor vasculogenesis remains controversial [4,9–14],
recent studies on human melanoma and brain tumors have
suggested that most tumor vasculature might be derived from
cancer cells rather than preexisting vessels [12–14], implicating a
mechanism of tumor vasculogenesis, which might play an
important role in tumorigenesis.
Vasculogenesis is a process of blood vessel formation through de
novo production of endothelial cells, originally observed during the
embryonic development. Tumor vasculogenesis denotes that some
cancer cells can spontaneously form blood vessels in tumor via
transdifferentiation into endothelial-like cells. A cancer resembles a
neo-organ, composed of various stages of developing cancer cells,
including precancerous stem cells (pCSCs) [15–17], cancer stem
cells (CSCs) [18–21] and cancer cells [16]. A cancer cell is
supposed to be developed from a process of tumor-initiating cells
(TICs)RpCSCsRCSCsRcancer cells [16]. CSCs have been
shown to promote tumor angiogenesis through secreting growth
factor VEGF [22], although their potential for transdifferentiation
into endothelial cells has not been demonstrated. Recently, we
have discovered that the precancerous stem cells (pCSCs),
representing the premalignant stage of developing CSCs, have
the potential for both benign and malignant differentiation
[15,16]. The pCSCs can develop into tumors in severe combined
immunodeficiency disease (SCID) mice, but not in bone marrow
(BM)-reconstituted (BMR) mice, blastocyst chimera mice, and
immunocompetent (IC) mice [15]. In the BMR mice, however,
pCSCs can differentiate into various types of tissue cells, including
endothelial-like cells, suggesting that they might have the capacity
to form blood vessels in tumorigenic environments [15]. To verify
the hypothesis, we have investigated the tumor vasculogenic
capacity of pCSCs in a murine model of lymphoma [15,23]. In the
pCSC-derived tumor, tumor blood vessels were essentially derived
from transplanted pCSCs. The pCSCs are much more potent in
tumor neo-vascularization compared to the differentiated tumor
monocytic cells (TMCs) derived from the same tumor. Various
types of human cancer cell lines that should contain pCSCs and
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tumor xenografts. Tumor vascular endothelial cells were inevitably
defective in phenotype and function with remarkable variations
between individuals. Consistently, most endothelial cells were
abnormal in human tumor vasculature. Thus, pCSCs can serve as
tumor vasculogenic stem/progenitor cells. The finding may
explain why anti-angiogenic cancer therapy trails are facing
serious challenge [25].
Results
Precancerous stem cells serve as progenitors for tumor
vasculogenesis
Since pCSCs has the potential to differentiate into endothelial-like
cells [15], we hypothesized that pCSCs may mediate tumor
vasculogenesis. To test the hypothesis, we transplanted intraperito-
neally (i.p.) or subcutaneously (s.c.) pCSCs (clone 2C4) or enhanced
green fluorescent protein (GFP)-expressing pCSCs (clone 2C4G2
derived from 2C4 clone) into SCID mice, as previously described
[15]. The tumors were removed at the size ,10 mm in diameter,
and prepared for paraffin-embedded sections. The sections were
stained with H & E and subjected to light and fluorescent
microscopic analysis. This method allowed us to precisely identify
and photograph pCSC-derived GFP
+ endothelial-like cells in well-
preserved tumor vasculature. As shown in Figure 1, mature blood
vessels were observed in both 2C4G2 (Fig. 1A) and 2C4 (Fig. 1E)
cell-derived tumors. In some areas, the pCSC-derived cells were
coalesced into the primary capillary plexus, developing into massive
capillary beds within tumors (Fig. 1).
All tumor cells derived from 2C4G2 clone exhibited strong
GFP-specific green fluorescence (Fig. 1B); whereas the tumor cells
derived from 2C4 clone demonstrated weak, non-specific auto-
fluorescence (Fig. 1F). Importantly almost all tumor blood vessels
or capillaries exhibited strong GFP-specific green fluorescence in
the 2C4G2-derived, but not in 2C4-derived tumors, regardless of
i.p. or s.c. transplanted tumors (Fig. 1B and F; red arrows indicate
representative vessels, which are the same as in Fig. 1A and E
indicated by green arrows), suggesting that not only tumor cells
but also tumor vascular endothelial cells (TVECs) can be derived
from pCSCs.
Since paraffin-embedded tissue sections usually demonstrate
high background of auto-fluorescence, we further verified pCSC-
derived TVECs in tumors by immunohistochemical (IHC)
staining of successive sections (Fig. 1C & G). Successive sections
from the same tumors either derived from 2C4G2 or 2C4 cells
were stained with the same high affinity rabbit monoclonal (mAb)
antibody to GFP followed by secondary HRP-conjugated goat
anti-rabbit IgG. As expected, the sections of 2C4G2 (Fig. 1C), but
not 2C4 (Fig. 1G) cell-derived tumors demonstrated GFP-positive
tumor cells as well as GFP-positive blood vessels, consistently with
the observations under fluorescent microscope (Fig. 1B & F).
Endothelial cells of capillaries in 2C4G2 cell-derived tumors were
strongly stained in nuclei and cytoplasm by mAb to GFP (Fig. 1D);
in contrast, no endothelial cells were stained by the same mAb to
GFP in 2C4 cell-derived tumors (Fig. 1H). Moreover, pCSCs not
only serve as progenitors for capillary endothelial cells, but also for
the endothelial cells of larger blood vessels, because endothelial
cells in various sizes of blood vessel of the tumors were GFP-
positive (Fig. 1 & Supplementary (s) Fig. 1C,E,F). Endothelial cells
were stained either in cytoplasm alone (Fig. S1E) or in both
cytoplasm and nuclei (Fig. S1F). Some of them may be weakly
stained (Fig. S1H). The weak stained endothelial cells were
unlikely non-specific, because the same antibody did stain
endothelial cells in 2C4 cell-derived tumors (Fig. 1G, H, & Fig.
S1A, B). This is consistent with our previous report that GFP in
pCSCs can be down-regulated when they were differentiating into
lineage-specific progenies, as demonstrated by flow cytometry
[15]. The finding supports that GFP may be down-regulated or
inactivated when progenitors differentiate into progenies [26].
The high affinity of rabbit mAb to GFP greatly promoted
specificity of IHC staining. The high specificity lends us capability
to directly investigate multipotency of pCSCs in well-preserved
tissue sections with almost null background (Fig. 1G). With the
advantage, we also identified pCSC-derived red blood cells (RBCs)
in tumors (Fig. 1D). In the capillary beds of 2C4G2 cell-derived
tumors, many of RBCs were GFP-positive with variable levels
(Fig. 1C & D). Even in the bigger blood vessels, GFP-positive
RBCs were also observed together with GPF-negative RBCs (Fig.
S1F,G). These GFP-positive RBCs are truly derived from 2C4G2
pCSCs, because no GFP-positive RBCs were detected in the 2C4
tumors using the same mAb to GFP (Fig. 1G & H, and Fig. S1A,
B). The significance of pCSC-derived erythrocytes in tumors needs
further investigation.
Taken together, the results directly confirm our previous finding
that pCSCs have the multipotency of differentiation [5,15].
Especially, the pCSCs can serve as tumor vasculogenic stem/
progenitor cells (TVPCs) to differentiate into TVECs and RBCs,
resembling hemangioblasts [27].
Precancerous stem cells express vascular progenitor
marker VEGFR-2
Both angiogenesis and vasculogenesis are mediated by VEGF
through binding VEGFR [28]. Receptor 2 for VEGF (VEGFR-2)
is most important for angiogenesis and vasculogenesis, because it
mediates almost all cellular response to VEGF [28]. Moreover,
VEGFR-2 is not only expressed on endothelial cells to promote
their proliferation [29], but also on the stem/progenitor cells to
mediate vasculogenesis [8]. To investigate whether the vasculo-
genic capacity of pCSCs is associated with VEFGR2-mediated
signaling pathway, we first examined whether pCSCs constitu-
tively expressed VEGFR-2 by flow cytometry. As shown in
Figure 2, ,5% of 2C4 cells constitutively expressed VEGFR-2
when cultured in vitro without exogenous cytokines, although they
did not express CD133, a marker for normal endothelial
progenitors [30]. To determine whether VEGFR-2 expression
on pCSCs is regulated by tumor environmental cues, we examined
the effects of cytokines on the expression in vitro., including Flt3
ligand (FL) [31], GM-CSF [32], IL-3 [33], IL-4 [34], IL-6 [35],
IL-7 [36] and IL-13 [37]. These cytokines can be detected in
tumor environments and have been reported having effects on
tumor angiogenesis. 2C4 cells were cultured for 3 days in the
presence of a cytokine alone or in combination, and analyzed for
cell proliferation and VEGFR-2 expression (Fig. 2). While all the
cytokines appeared to promote pCSC expansion except for IL-6,
the viable cell counts were marginally or significantly increased
only in the cultures with GM-CSF, IL-13, FL, or IL-13 plus FL,
compared to the cultures absent of exogenous cytokines (Fig. S2).
There was no significant synergistic or additive effect between
them (Fig. S2). VEGFR-2 expression on pCSCs was significantly
up-regulated by FL, IL-13, and GM-CSF, but not by IL-3, IL-4,
IL-6 and IL-7 (Fig. 2). Interestingly, IL-4 almost completely
inhibited VEGFR-2 expression induced by GM-CSF (Fig. 2). This
may explain why IL-4 has strong anti-tumor activity [34,38].
Although VEGFR-2 expression on pCSCs was significantly up-
regulated by FL, IL-13 and GM-CSF, only few VEGFR-2
+ cells
expressed CD133 (Fig. 2A), indicating that VEGFR-2-expressing
pCSCs is essentially distinct from normal endothelial progenitors
[30]. The result suggests that the vasculogenic capacity of pCSCs
is associated with VEGFR-2 expression.
Tumor Vasculogenesis
PLoS ONE | www.plosone.org 2 February 2008 | Volume 3 | Issue 2 | e1652Figure 1. The contribution of pCSCs to tumor vasculogenesis. The pCSCs (clone 2C4 or 2C4G2) were inoculated s.c. or i.p. (5610
6/mouse;
n=10/group) into SCID mice. About 40,100% of the mice developed tumors, which grew so fast once they were palpable that the mice had to be
sacrificed within 7 d of the palpation [15]. The tumors were harvested and fixed with 10% formalin in PBS. The sections were stained with H & E, and
subjected to microscopic analysis simultaneously under the bright (A & E) and fluorescent fields (B & F), respectively (A & B). To verify the results from
fluorescent microscopy, successive sections were subjected to IHC staining with rabbit mAb to GFP (1:300 dilution) followed by HRP-conjugated goat
anti-rabbit IgG (C, D, G & H). The data shown are a representative of tumor micrographs. A–D, A tumor from a mouse inoculated with GFP-expressing
cells (2C4G2); the insets in C were enlarged as shown in D, demonstrating GFP-positive TVECs and RBCs. E–H, A tumor from a mouse transplanted
with non-GFP-expressing cells (2C4), and the insets in G were enlarged as shown in H, demonstrating GFP-negative TVECs and RBCs. C and G are
successive sections of A and E, respectively, and were stained with the same rabbit mAb to GFP. Arrows in A and E indicate the same blood vessels in
B and F, respectively, which were GFP-positive or GFP-negative.
doi:10.1371/journal.pone.0001652.g001
Tumor Vasculogenesis
PLoS ONE | www.plosone.org 3 February 2008 | Volume 3 | Issue 2 | e1652Figure 2. The effect of cytokines on VEGFR-2 expression in pCSCs. The pCSCs (2C4 clone) were cultured in 2.0 ml of R10F (1610
5 cells/well)
in 24-well plates in the presence of cytokine IL-3 (50 ng/ml), IL-4 (20 ng/ml), IL-6 (50 ng/ml); IL-7 (50 or 100 ng/ml), IL-13 (50 ng/ml), GM-CSF (40 ng/
ml), or FL (200 ng/ml) alone or in combination (GM-CSF+IL-4; FL+IL-13; IL-3+IL-6). Control cultures were absent from exogenous cytokines. The cells
were harvested 3 days later, stained with FITC-conjugated rat mAb to murine CD133 and PE-conjugated mAb to murine Flk-1 (VEGFR-2), and
analyzed by flow cytometry [15]. A, Data shown are contour plots of a representative experiment. The numbers in quadrants indicate the percentage
of each subpopulation. B, Shown is the percentage of Flk-1
+ cells of pCSCs derived from four independent experiments. **, p,0.01; * p,0.05,
compared to the cultures without exogenous cytokines.
doi:10.1371/journal.pone.0001652.g002
Tumor Vasculogenesis
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endothelial-like cells in responding to hypoxia
Since hypoxia can induce progenitors to differentiate into
endothelial cells [39], we examined whether pCSCs could
differentiate into endothelial-like cells in responding to hypoxia.
2C4 cells were cultured in a hypoxic culture system to induce their
differentiation (Fig. 3). Four days after cultivation in the matrigel-
containing or suspension medium, pCSCs were altered significantly
in morphology under hypoxic condition compared to normoxic
culture condition (Fig. 3a). Elongated endothelial-like cells were
observed, especially in the suspension cultures (Fig. 3A), despite no
typical endothelial cell tube was formed. Some elongated cells were
aligned in tandem (data not shown). Under normoxic condition,
pCSCs retained round inmorphology (Fig.3A). In addition,hypoxic
culture condition also significantly suppressed pCSC expansion in
vitro (Fig. 3B). This may be in part related to differentiation-induced
cell death [15], because apoptotic cells were found in the colonies of
differentiating cells (Fig. 3A, arrows). Flow cytometric analysis
demonstrated that the frequency of CD45
+CD31
+ endothelial
precursors was significantly increased in the hypoxic cultures
compared to that in normoxic cultures [40], despite overall
frequency was lower than we expected (Fig. 3C). The low frequency
ofCD31
+cells mightreflect that only smallnumbersof pCSCs could
differentiate into endothelial-like cells. This may be related to their
genetic instability and environmental cues provided by the culture
system. Note that the level of CD31 expression was proportional to
that of CD45 expression (Fig. 3C), and the isotype antibody control
excluded the possibility of non-specific staining. Some pCSCs
cultured in normoxic condition also expressed CD31 (Fig. 3c),
probably correlating with constitutive expression of CD31 mRNA in
pCSCs (Fig. 3D & Fig. S3).
Interestingly, most pCSCs cultured in hypoxia condition
remained CD31-negative (Fig. 3c), suggesting that pCSC-derived
endothelial-like cells were essentially abnormal. Thus, we further
examined the effect of hypoxia on the expression of angiogenic/
vasculogenic genes as well as endothelial cell-related genes in
pCSCs, including VEGF, Ang-1, and VEGFR-2, hypoxia-induced
factor-1a (HIF-1a), CD31, and endoglin (CD106). Fig. 3D shows a
representative experiment of RT-PCR analysis of kinetic expres-
sion of the genes in pCSCs under normoxic or hypoxic culture
condition, and the results were quantitated as showing in Fig. S3.
The genes examined were constitutively expressed in pCSCs
cultured in normoxic condition (Fig. 3d & Fig. S3A). However,
VEGF and HIF-1a were expressed in higher level than Ang-1,
VEGFR-2, endoglin, and CD31 (Fig. S3A). Interestingly all the
genes examined in pCSCs were unchanged or down-regulated
within 48 hrs of hypoxic culture. At 72 hrs of culture, hypoxia
induced an increased expression of Ang-1, VEGFR-2, endoglin
and CD31, but not HIF-1a and VEGF (Fig. S3B). In particular,
Ang-1 was dramatically up-regulated by ,5 folds (Fig. S3B). The
expression pattern was also detected by real-time PCR at 96 hrs of
culture (Fig. 3E, compared Fig. S3A). The transcripts of Ang-1,
VEGFR-2, endoglin and CD31 were significantly up-regulated
(.2 folds increase); whereas VEGF and HIF-1a remained
unchanged (,1 fold reduction). The unsignificant alteration of
VEGF and HIF-1a in hypoxic culture condition might be related
to their high level of constitutive expression in pCSCs (Fig. S3B) or
the abnormality of pCSCs as endothelial progenitors. The results
suggest that pCSCs, like in vivo ([15] & Fig. 1), can also differentiate
into endothelial-like cells in responding to hypoxia in vitro.
Precancerous stem cells are more potent than TMCs in
vasculogenesis
The capacity of vasculogenesis may determine the rate of tumor
growth. We have reported that pCSCs are more potent in
tumorigenesis in SCID mice than differentiated TMCs from the
Figure 3. Differentiation of pCSCs in responding to hypoxia. The pCSCs (clone 2C4; 5610
4/well) were cultured in 0.5 ml (hypoxia) or 2.0 ml
(normoxic) of R10F medium or Matrigel. From day 3,4 of cultures, the cells in the suspension medium or Matrigel are morphologically altered in the
hypoxic culture but not in normoxic cultures (A). The cells were harvested on day 4 of cultures, enumerated (B), and analyzed for CD31 and CD45
expression by flow cytometry (C), or harvested on day 1, 2, 3 and 4 for angiogenic factor expression revealed by RT-PCR (D, day 1,3) or real-time PCR
(E, day 4). A, the phase contrast microphotographs of cell morphology of pCSCs cultured in Matrigel-containing or suspension medium under the
normal or hypoxic condition, which were taken at day 4 of culture. Arrows indicate apoptotic cells. B, Hypoxia inhibited proliferation of pCSCs. Data
shown are pooled results from two of four reproducible experiments (n=4 well/group/expt). C, phenotypic analysis of the pCSCs cultured in the
hypoxic condition using flow cytometry. The number in each quadrant represents the percentage of the gated live cells. D and E, Expression of
vascular growth factor and endothelial cell marker genes in the pCSCs responding to hypoxia. The cells were harvested at day 1, 2, and 3 of cultures
and analyzed by RT-PCR (D), or harvested at day 4 and analyzed by real-time PCR (E). Data shown are representatives from 3,4 experiments, and the
data of D was also quantitated and shown in Fig. S3.
doi:10.1371/journal.pone.0001652.g003
Tumor Vasculogenesis
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capacity between pCSCs and TMCs. pCSCs (2C4) and TMCs
(clone 3B11) were transplanted s.c. into SCID mice, respectively.
Consistently with our previous report [15], pCSCs had more
potent capability than differentiated TMCs to form a new tumor.
The tumors in the mice that received 2C4 cells were palpable at
least 5 days earlier than those in the mice that were injected with
3B11 cells (Fig. 4a; top panel). Moreover, the growth kinetics of
pCSC-derived tumors was much faster than TMC-derived
tumors, and the size of pCSC-derived tumors was 4 ,5 times
bigger than that of TMC-derived tumors at the time of harvest
(Fig 4a, bottom panel). Interestingly, the sex hormones appeared
to affect the growth of pCSC-derived but not TMC-derived
tumors, because the former but not the latter grew significantly
faster in male mice than in female mice (Fig. 4a), suggesting that
estrogen affect pCSC but not TMC expansion in vivo.
The different growth rate between pCSC- and TMC-derived
tumors may be associated with their capacity of tumor
vasculogenesis. Histological analysis revealed that the vasculature
in pCSC-derived tumors was much more mature and dense than
in TMC-derived tumors (Fig. 4b). Most capillary cells exhibited
endothelial-like morphology in pCSC-derived tumors, while most
cells lining up the vessel wall of TMC-derived tumors were
monocytic in morphology (Fig. 4b). Most vessels in the TMC-
Figure 4. Comparison of vasculogenic capacity between pCSCs and TMCs. SCID mice were inoculated s.c. with pCSCs (2C4) at left groin and
TMCs (3B11) at right groin (5610
6/mouse). Tumor incidence and size were monitored every other day (A), and pCSC- or TMC-derived blood vessels
were analyzed by H & E and IHC staining of paraffin-embedded tumor sections (B), and the blood vessels in each section were counted under high
power microscopy (C). Constitutive expression of angiogenesis-related genes between pCSCs and TMCs was compared before inoculation. A, tumor
incidence and size: *, p,0.05; when compared between male (n=5) and female (n=5) mice. B, Analysis of pCSC- or TMC-derived tumor vasculature:
upper panel: H. & E staining; middle panel: IHC staining specific for neomycin; and bottom panel: IHC staining controls with normal rabbit IgG as
primary antibody. Arrows in the middle and bottom panels indicate neomycin-positive or negative TVECs or blood vessels at various developing
stages. C, Comparison of the numbers of neomycin
+ blood vessels between pCSC- and TMC-derived tumors: Neomycin
+ blood vessels were counted
under the 4006field of light microscope, and expressed as the number of per high-power field (HPF). Each tumor was counted for three successive
sections, and 5 tumors were counted per group (**, p,0.01, as compared between pCSC and TMC-derived tumors). D, Constitutive expression of
angiogenesis-related genes between pCSCs and TMCs: The 2C4 and 3B11 cells were harvested at log-phase of growth and analyzed by
semiquantitative RT-PCR for 25, 30 and 35 cycles, respectively (Lane 1, 2C4; lane 2, 3B11).
doi:10.1371/journal.pone.0001652.g004
Tumor Vasculogenesis
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formation, and some of which were unexpectedly filled with red
blood cells [Fig 4b (3B11); top panel]. To determine the cell origin
of tumor vasculature, we examined neomycin-expressing cells
within tumor vasculatures by immunohistochemical (IHC) stain-
ing, as both 2C4 and 3B11 cells carried neomycin gene integrated
into genome [15]. As shown in Fig. 4b (middle panel), most cells
lining on vascular lumens were derived from pCSCs or TMCs,
because they were strongly stained by mAb to neomycin. Note that
the expression pattern of neomycin was different between pCSCs
and TMC-derived tumors. In pCSC-derived tumors, neomycin was
strongly detected in cytoplasm but weakly in nuclei; however, it was
strongly detected in both cytoplasm and nuclei in TMC-derived
tumors. The number of neomycin-positive blood vessels per high-
power field (HPF) was significantly higher in pCSC-derived tumors
than in TMC-derived tumors (Fig. 4c). The results suggest that both
pCSCs and TMCshave the potential of vasculogenesis, although the
vasculogeniccapacitybetween them is different. Thus, the difference
of growth rate between pCSCs and TMCs appears to be correlated
with their capacity of vasculogenesis.
To determine whether the differential capacity of vasculogenesis
between the pCSCs and TMCs was associated with differential
activation of vasculogenic genes between them, we examined
constitutive expression of vasculogenic and endothelium-related
genes in these lines using semiquantitative RT-PCR, including
VEGFR1/2/3, VEGF, Ang-1/2, Tie1/2, HIF-1a, endoglin,
CD31 and von Willebrand factor (VWF). While pCSCs and
TMCs expressed comparable levels of HIF-1a, VEGFR-2, VEGF
and Ang-1 transcripts, the pCSCs expressed lower levels of
transcripts of VEGR1 and Tie1/2 than TMCs, and even did not
constitutively express Tie1, Tie2, and Ang-2 (Fig. 4d). Transcripts
of endothelial cell-related genes CD31 and endoglin (CD105), but
not VWF were detected in both pCSCs and TMCs (Fig. 4d).
Taken together, the difference in tumor vasculogenic capacity
between pCSCs and TMCs seems not associated with the
expression levels of vasculogenic genes, but may be related to
the stem-like property of pCSCs [15].
Human tumor cell-derived endothelial-like cells are
abnormal in phenotype and function
To determine whether human tumor vasculature was also
derived from tumor vasculogenic stem/progenitor cells (TVPCs)
[16], we examined the origin of tumor vasculatures in human
tumor xenografts. Since there is no human pCSC clone available,
we used human tumor cell lines, because they may contain pCSCs
and/or CSCs [16,24]. Human leukemic cell line MV411 [41],
breast cancer cell lines MDA-MB-231 (ATCC HTB26) or MDA-
MB-468 (ATCC HTB132) were injected s.c. into SCID CB17
mice, all of them grew out in the recipients (data not shown). The
tumors were removed at the size 10,15 mm in diameter, and
subjected to histological and IHC analysis, as described above.
The tumor cell-derived vasculogenic progenitors or vascular
endothelial-like cells, which were lining on vessel walls, were
determined by anti-human CD45, CD31, CD34, or VWF.
In the MV411-derived xenograft lymphomas, a high density of
capillary network was observed, and some capillaries were filled
with RBCs (Fig. 5A-a). Most blood vessels were derived from
MV411 cells because they were strongly stained by anti-human
CD45 and CD31 (Fig. 5A-e, f). Some mosaic vessels were
observed, in which few endothelial-like cells did not express CD45
(Fig. 5A-e, arrow), suggesting that they might be derived from host
endothelial progenitors. However, it was not certain whether these
CD45-negative endothelial-like cells were derived from the
progenitors of recipients, because tumor vascular endothelial cells
could be abnormal and thus may lack CD45 [42]. Interestingly
CD 34 in all tumor vascular endothelial cells was undetectable
(Fig. 5A-c) and VWF expression was remarkably variable among
tumor vascular endothelial-like cells (Fig. 5A-g, h). The results
suggest that tumor cell-derived vascular endothelial-like cells were
defective in phenotype and functions. The failure to demonstrate
CD34 in tumor vascular endothelial cells was not caused by the
quality of anti-CD34 antibody because the same antibody strongly
stained the normal endothelial cells in the placental sections
mounted on the same slides (Fig. 5A-d). To further verify that
human vascular endothelial markers detected by IHC staining were
truly derived from MV411 cells, we further examined the transcripts
of CD31, CD34, CD45 and VWF in MV411 cells before (Fig. 5B)
and after transplantation (Fig. 5C). MV411 cells constitutively
expressed the transcripts of CD31, CD34, CD45 but not VWF,
which were specifically detected by respective human-specific but
not murine-specific primers (Fig. 5B). The transcripts of these
markers were also detected in MV411 cell-derived tumors although
with variable levels among individuals (Fig. 5C). The transcripts of
murine CD31, CD34, CD45 and VWF were also detected in some
tumors with variable levels (Fig. 5C), suggesting that host endothelial
progenitorswereinvolved intumorangiogenesistosomeextent.The
specificity of these primers was verified by their respective capability
to detect corresponding mRNAs in MV411 and 2C4 cell lines
(Fig. 5B). Since 2C4 did not express CD45 [15], murine CD45
mRNA was not detected in 2C4 cells (Fig. 5B), but was detected in
xenograft tumors (Fig. 5C). Overall, the results strengthen the
conclusion that MV411 cells contain TVPCs.
Consistently, in the tumor xenografts derived from human breast
cancer cell lines (MDA-MB-231 and MDA-MB-486), tumor cell-
derived endothelial-like cells were observed. However, little CD45
+,
CD31
+,C D 3 4
+, and VWF
+ cells were detected among tumor
endothelial-like cells. This is unlikely associated with angiogenesis,
because recipient-derived vascular endothelial cells were not
detectable in most capillary network using anti-murine CD31
antibody (not shown). Again, the abnormal phenotype of tumor
vascular endothelial-like cells may be related to the defective
differentiation of the TVPCs derived from tumor cell lines.
To further confirm that TVECs were defective in phenotype
and function, we examined expression of CD45, CD34, CD31 and
VWF in the native human cervical and breast cancers. As
expected, the phenotype and function (VWF expression) of tumor
endothelial cells in these cancers were essentially abnormal (Fig. 6).
The expression pattern of CD45, CD34, CD31 and VWF in both
cervical and breast cancer was highly variable between individuals
being examined (Fig. 6). No consistent phenotypic pattern between
individuals or between types of cancer could be drawn based on
IHC staining. Few CD45
+ vascular cells might represent TVPCs
(Fig. 6). Overall the results suggest that most, if not all, human
TVECs are derived from TVPCs, and thus are defective in
phenotype and function.
Discussion
Tumor vascularization is critical for tumor growth, invasion and
metastasis. Traditionally tumor vasculature has been considered to
be derived from pre-existing blood vessels through a process of
angiogenesis [1–3,43]. However, increasing data have suggested
that tumor vasculature may be derived from cancer cells through a
process of vasculogenesis [12–14]. In this study, we for the first
time provide evidences that tumor vasculature can be derived at
least from pCSCs, a population of cancer cells representing
premalignant stage of developing CSCs [15,16], suggesting that
pCSCs are important for tumor vasculogenesis. This finding not
Tumor Vasculogenesis
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vasculogenesis (TVPCs) but also explain why current anti-
angiogenic cancer therapy trials are facing serious challenge [25].
Although the prevailing concept argues that tumor neo-
vasculature is derived from pre-existing blood vessels or bone-
marrow (BM)-derived circulating endothelial progenitors [4,9], it
has been shown that the frequency of BM-derived endothelial cells
were very low in tumor neo-vasculature [10], suggesting that
tumor vasculature may be derived from tumor cells [12,13,44].
However, there is no evidence so far directly confirming that
tumor cells can serve as a progenitor for tumor vasculogenesis,
despite some studies have indirectly supported the hypothesis
[12,13,44]. In this study, we directly demonstrate that pCSCs can
serve as progenitors for tumor vasculogenesis. The conclusion is
supported by the following evidences: first, the pCSCs have the
potential to differentiate into endothelial-like cells in vivo [15] and
in vitro; second, pCSC-derived TVECs were dominant in tumor
vasculature; third, some pCSCs constitutively expressed the
receptor VEGFR-2 (Flk-1) and ligand VEGF, which may drive
pCSC-derived TVPCs to differentiate into endothelial cells
probably through an autocrine mechanism [45]; fourth, instead
of freezing, fixation of pCSC-derived tumors with formalin to
preserve fine structure of tumor vasculatures allowed us to directly
visualize the pCSC-derived GFP
+ endothelial cells that aligned on
vessel walls; fifth, the pCSCs responded well to both hypoxia and
angiogenic cytokines; Sixth, the blood vessels in human cancer
xenografts were also overwhelmingly derived from the transplant-
ed human tumor cell lines, which should contain pCSCs and/or
CSCs [22,24]. Subcutaneous transplantation of human MV411
cells into SCID mice led to the formation of xenograft lymphoma,
in which almost all vascular endothelial cells were derived from
MV411 cells. Finally, TVECs in human native cancers such as
cervical and breast cancers were found to be defective in
phenotype and function (VWF expression).
It has long been observed that the endothelial cells of tumor
vessels are abnormal concerning their morphology and phenotype
as revealed by electronic microscopy [44,46] and IHC staining
[47], respectively. This abnormality exhibited as the mosaic blood
vessels, in which, e.g., both CD31
+CD105
+ endothelial cells and
CD31
2CD105
2 cells formed luminal surface [47]. The abnormal
phenotypes of tumor vascular endothelial cells had been ascribed
to the tumor cells that aligned on the defective walls of tumor
vessels [47], or to the tumor environments which caused abnormal
differentiation of normal endothelial progenitors [48]. However,
our studies indicate that these abnormal vascular cells, at least
Figure 5. Vasculogenic capacity of human tumor cell lines.
Human Leukemia/lymphoma cell line MV411 was injected s.c. into groin
of SCID mice (5 610
6/mouse; n=4). MV411 developed into solid tumor
palpable at day 15 of injection and the tumors were harvested 26 days
after injection. The tumors were harvested for RNA extraction or fixed in
10% formaldehyde. A, Activity of TVPCs in human tumor cell lines: the
sections of xenograft tumors were stained with H. & E. (a) or stained
immunohistochemically with rabbit IgG (b) or rabbit anti-human CD34
(c & d), CD45 (e), CD31 (f) or VWF (g & h), followed by HRP-conjugated
secondary antibody. In the d, the sections of human placenta were
stained as positive control for CD34 in the same slides of c. The arrow in
r
e indicates a CD45-negative endothelial-like cells lining on the wall of a
blood vessel. Original magnification of micrographs: 6400 (numbers in
the micrographs indicate real magnification shown). B & C, Expression
of endothelial-related genes in the human MV411 tumor cells before (B)
and after transplantation (C): Before transplantation, the MV411 and
2C4 cells were harvested at log-phase of growth, and extracted for total
RNA. The mRNAs from MV411 and 2C4 cells were probed with both
human and murine primers specific for CD45, CD34, CD31, VWF and b-
actin mRNAs, respectively. Note that murine primers of b-actin cross-
reacted to human b-actin, vice versa. The data shown are representative
of three experiments. Murine 2C4 cells were used as species specific
negative and positive controls for human- and murine specific primers,
respectively (B). After transplantation, three MV411 cell-derived tumors
were extracted for total RNA as described in A and probed with human
and murine primers of CD45, CD34, CD31, VWF and b-actin,
respectively. Lane 1,3: each individual tumor; Lane 4: H2O, used for
technical control for RT-PCR (C).
doi:10.1371/journal.pone.0001652.g005
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and CSCs rather than from normal progenitors. Expression of one
or two endothelial markers on tumor vascular endothelial cells
does not seem to sufficiently prove that they are derived from
normal progenitors. Examination of vascular endothelial cell
markers in tumor xenografts and the specimens of human cervical
and breast cancer revealed that little normal endothelial cells could
be detected in these cancers. None of the cases examined of each
type of cancer expressed a complete array of normal endothelial
markers, suggesting that these endothelial cell markers are
randomly expressed depending on environmental cures. Consis-
tently, pCSCs in responding to hypoxia expressed little up-
regulated CD31, although their morphology was changed into
endothelial-like and their genes for vascular growth were up-
regulated. The pCSC-derivation of TVECs may explain why they
are phenotypically multifaceted [42]. It is likely that most tumor
vasculature are derived from pCSCs and/or CSCs, especially from
those having the potential to differentiate into endothelial-like cells
[15,16]. The markers for TVPCs remain to be elucidated.
However, VEGFR-2 might be a candidate marker of TVPCs,
because VEGFR-2-mediated signaling is required for both
angiogenesis and vasculogenesis [6,8,45,49,50].
A critical question, however, remains to be answered: what is
the status of angiogenesis in tumor neo-vascularization? While
Lyden et al showed that impaired recruitment of BM-derived
endothelial and hematopoietic precursor cells blocked tumor
angiogenesis and growth [9], Larrivee et al demonstrated that the
contribution of BM-derived precursor to tumor angiogenesis is
minimal [10]. The argument appears to be reconciled by the
recent finding showing that BM-derived precursors seems
dominant in early tumor but greatly diluted in later tumor [51].
Combined with our findings, we propose that angiogenesis is
required for efficient tumor vasculogenesis. In early tumor,
endothelial cells from pre-existing blood vessels or circulating
endothelial progenitors may proliferate and sprout surrounding
cancer cell aggregates; simultaneously tumor cell-derived progen-
itors start a process of vasculogenesis. In animal models as well as
human tumor xenograft models, we observed various stages of
developing blood vessels, as outlined in Fig. 7. Initially the
progenies of pCSCs or CSCs form an aggregate in tumorigenic
niches (Fig. 7a, e). With the enlargement of the aggregates, pCSCs
or CSCs that have the properties of TVPCs line up to form
branching lumens and tubes (Fig. 7b, e). The tubes were extended
and elongated (Fig. 7c, e), and the newly formed vasculature
merged with host vessel sprouts from pre-existing blood vessels
surrounding tumor capsule to form functional neo-capillary
network (Fig. 7d, e). Without angiogenesis, tumor vasculogenesis
might be aborted [9]. This model emphasizes that the formation of
Figure 6. Defective phenotype and function of human TVECs. The sections of human cervical (n=25) and breast cancer (n=5) specimens
were stained immunohistochemically with mAbs to CD45, CD31, CD34, or VWF. None of the cases examined demonstrated normal profile of
endothelial cell markers, and none of the markers examined was detected in all tumor blood vessels. The insets indicate CD45
+ endothelial-like cells
within blood vessels; and arrow heads indicate that the endothelial-like cells lining upon blood vessels did not express relevant markers examined.
The data shown are representative micrographs of human cervical and breast cancer. Original magnification: 6400; final magnification shown: 672.
doi:10.1371/journal.pone.0001652.g006
Tumor Vasculogenesis
PLoS ONE | www.plosone.org 9 February 2008 | Volume 3 | Issue 2 | e1652tumor vasculature requires the mechanisms of both angiogenesis
and vasculogenesis, and may explain the respective roles of
angiogenesis and vasculogenesis in tumorigenesis (Fig. 7e).
Another important issue is the factors that affect tumor
angiogenesis and vasculogenesis. It is well-known that both
angiogenesis and vasculogenesis are mediated by the same growth
factors and receptors. Most important factors are VEGF and Ang-
1/2, which bind receptors VEGFR-1/2 and Tie1/2, respectively
[52,53]. Among them, VEGFR-2-mediated signaling is critical for
vasculogenesis in embryonic and tissue vasculogenesis [8,54], and
Ang-1/2 and Tie-1/2 are mainly responsible for angiogenesis
[53,55]. While the vascular growth factors mainly determine the
Figure 7. The putative cellular mechanism for tumor vasculogenesis. TVPCs within tumor cell aggregates line-up along the branching lumen
(A, circles), and form tubes (A & B, green arrows). The tubes are extended, elongated, and become neo-vasculatures (C, green arrow). The newly
formed vasculature (neomycin
+; red arrow) merged with host blood vessels (neomycin
2; green arrow) to form the neo-vasculature networks (D). E, A
schematic process of tumor vasculogenesis illustrated based on A,D. The figure A is derived from a 3B11 tumor. Original magnification of
micrographs: 6600.
doi:10.1371/journal.pone.0001652.g007
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vasculogenesis seems to be limited. The notion is supported by the
fact that TMCs that produced comparable or even higher levels of
growth factors or receptors had much less capacity of tumor
vasculogenesis, when compared to pCSCs. The different vascu-
logenic capacity between pCSCs and TMCs does not seem to
associate with expression of VEGFR-2 on these cells, because they
expressed comparable VEGFR-2 transcripts. TMCs expressed
higher levels of VEGFR1 and Tie2 than that of pCSCs. VEGFR1
has been shown to limit the mitogenic function of VEGFR-2
[56,57] and, thus might limit VEGF-induced vasculogenesis.
Tie2/Ang-2 signaling has been shown anti-angiogenic [58,59].
Whether vasculogenic capacity of TMCs is limited by these two
factors remains elusive.
As discussed above, examination of human cervical and breast
cancer specimen revealed that most blood vessels in invasive
cancer were derived from tumor cells because little normal
endothelial cells were detected. This observation suggests that in
addition to capability to produce vascular growth factors, the
status of vasculogenesis in tumor may be determined by frequency
and intrinsic properties of tumor cell-derived vascular progenitors.
This explains why most clinical trials of anti-angiogenic therapy
have failed to block tumor growth [25]. Currently anti-angiogenic
drugs are screened by using in vitro angiogenic models composed of
normal endothelial progenitors [25]. As a result, while screened
drugs are effective on normal endothelial progenitors, they may be
resisted by TVPCs. Thus, pCSCs and CSCs may be main targets
for anti-angiogenic cancer therapy. In addition, cytokines such as
GM-CSF, FL and IL-13 can up-regulate VEGFR-2 expression on
pCSCs. Whether these factors promote pCSC-mediated vasculo-
genesis needs further investigation.
In addition to pCSCs, we also show that TMCs have the potential
of tumor vasculogenesis, suggesting that pCSCs are not a sole
population having activity of TVPCs. This is not surprising, because
monocytes are highly plastic in differentiation [23]. It has been
reported that monocytes or myeloid cells have the capability to
transdifferentiate into endothelial cells [60–62]. Monocytes have
been shown to play an important role in tumor angiogenesis [63].
On the other hand, activated monocytes can secrete soluble (s)
VEGFR1 to inhibit angiogenesis [64]. It should be noted that
vasculogenic capacity of TMCs was less than that of pCSCs, despite
both of them are derived from the same tumor [15,23], and that
TMCs expressed high level of VEGFR1. Whether TMCs can
produce sVEGFR1, leading to defective tumor vasculogenesis; or
their vasculogenic capacity is hierarchically reduced when they
developed frompCSCs.Furtherelucidatingtheseissueswillfacilitate
understanding of the mechanisms underlying tumor vasculogenesis.
A solid tumor has been considered a neo-organ in the body,
consisting of various components including stromal and paren-
chymal cells; the latter are composed of pCSCs, CSCs and
terminal differentiated cancer cells [16]. Its malignancy is
determined essentially by the degree of uncontrollable cell growth,
neo-vascularization, and the capacity of metastasis. Resembling
normal organs, which may be replenished by tissue stem cells,
tumor may be replenished by pCSCs and/or CSCs. On the basis
of our previous finding [15], we here further reveal that pCSCs
can serve as progenitors for tumor vasculogenesis (TVPCs) as well
as progenitors of RBCs in tumors.
Methods
Mice, cell lines, and reagents
SCID CB17 mice were used at age of 8–12 wk. We bred and
maintained the mice in an animal pathogen-free facility at The
Ohio State University Medical Center. Murine pCSC clones 2C4
and 2C4G2 and monocytic tumor cell (TMC) line 3B11 from the
same tumor were generated and maintained in our laboratory
[15,23]. The GFP-expressing 2C4G2 cells were derived from 2C4
clone [15]. 2C4 and 3B11 carry neomycin gene in the genome
[15]. Human leukemic cell line MV411, and breast cancer cell
lines MDA-MB-231 and MDA-MB-486 were maintained in our
laboratory. Murine mAbs to human CD31, CD45, and VWF (von
Willebrand factor VIII) as well as isotype mAbs were purchased
from Dako (Denmark); and murine mAb to human CD34 mAb
was purchased from Immunotech Inc. Monoclonal rabbit anti-
GFP antibody was purchased from Epitomic Inc (Burlingame,
CA). Polyclonal rabbit anti-neomycin antibody was provided by
Upstate Cell Signaling Solutions (Lake Placid, NY). Recombinant
murine GM-CSF, Flt3 ligand (FL), IL-3, IL-4, IL-6, IL-7 and IL-
13 were purchased from PeproTech. Fluorescent dye-conjugated
antibodies were purchased from BD Science.
Cell culture
The cell lines were maintained in R10F (RPMI 1640 plus 10%
fetal calf serum supplemented with 5 mM glutamine, 50 mM2 -
mecaptoethonal, 100 U/ml penicillin, and 100 mg/ml streptomy-
cin) [15,23]. To investigate the effect of cytokines on VEGFR-2
expression in pCSCs, the cells were cultured in R10F for 3 days in
the absence or presence of cytokines alone or in combination,
including recombinant murine GM-CSF, Flt3 ligand (FL), IL-3,
IL-4, IL-6, IL-7 and IL-13. To induce pCSC differentiation into
endothelial cell-like cells in vitro, the pCSCs were cultured in
hypoxic medium as indicated in figure legend.
Tumor transplantation
SCID CB17 mice were injected s.c. with 5610
6 2C4, 2C4G2,
3B11, MDA-MB-231, MDA-MB-486, or MV411 cells. Tumor
incidence and size were monitored starting from 1 wk after
inoculation, once every other day. The mice were sacrificed when
one of the mice in a group bearing tumor about 10,15 mm in
diameter. Tumors were harvested for histological and IHC
staining [15].
RT-PCR
Total RNA was extracted from cell lines. The cDNA was
generated by reverse transcription using SuperScript III First-
Strand Synthesis System ( Invitrogen, CA) and oligo (dT) in a
20 ml reaction containing 1 mg of total RNA, which was pretreated
with RNase-free DNase I (Qiagen, CA) to eliminate contaminat-
ing genomic DNA. Briefly, an aliquot of 0.5 ml cDNA was used in
each 25 ml PCR reaction, using PlatinumH Taq DNA Polymerase
High fidelity (Invitrogen, CA). The following conditions were used:
an initial denaturation at 95uC for 5 min followed by denaturation
at 94uC for 30 seconds, annealing at 58uC for 30 seconds and
extension at 68uC for 1 min for a total of 25, 30 or 35 cycles. PCR
products were analyzed by 2.0% agarose gel. The sequence of the
primers used is listed in supplementary Table S1.
Real-time PCR
Real-time PCR was performed on ABI 7500 Real-Time PCR
System (Applied Biosystems, Inc., CA). cDNA was combined with
primer sets and Power SYBRH Green PCR Master Mix (Applied
Biosystems, Inc., CA). The sequence of the primers used is listed in
supplementary Table S1. The PCR conditions were as follows:
95uC for 10 s, 60uC for 1 min, 45 cycles. Gene expression levels
were calculated relative to the house-keeping gene b-actin by using
Sequence Detection Software (version1.3.1) (Applied Biosystems,
Inc., CA).
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system
The pCSCs (5610
4/well) were cultured in 0.5 ml (hypoxia) and
2.0 ml (control) R10F medium with or without BD Matrigel
TM
(1:4 dilution) for 4 days in 24-well plates in triplicate. The
morphologic alteration was monitored under phase contrast
microscope every day. In some experiments, the cells were
harvested on day 1, 2, and 3 for RT-PCR or real-time PCR
analysis of the genes of angiogenic factors and endothelial cell
markers. For flow cytometric analysis, the cells were harvested and
stained where indicated.
Flow cytometry
Single cells harvested from cultures were stained with
corresponding mAbs, and then analyzed by flow cytometry, as
described previously [15,23].
Histological and immunohistochemical analysis
Tumor specimens were fixed in formalin and embedded in
paraffin for pathological and immunohistochemical analysis, as
described [15,23]. Human specimens of cervical and breast cancer
were provided by the Tissue Procurement Shared Resource
(TPSR), Comprehensive Cancer Center, Ohio State University.
Sections (4,5 mm) were stained by H. & E. for pathological
analysis, or immunostained with a monoclonal or polyclonal
primary antibody followed by a horseradish peroxidase (HRP)-
conjugated secondary antibody. The immunostained sections were
counterstained with haematoxylin.
Statistical analysis
Data were statistically analyzed by one-way ANOVA or
student-T test. Two-tailed T test was performed except for where
indicated. P-value#0.05 was considered significant; and p-
value#0.01 was considered highly significant.
Supporting Information
Figure S1 Multipotency of pCSCs in tumorigenesis 2C4G2 and
2C4 cell-derived tumor tissue sections were prepared and stained
with rabbit mAb to GFP followed by HRP-conjugated goat anti-
rabbit IgG, as described in Fig. 1. In the 2C4 cell-derived tumor
sections, none of sections were GFP-positive (A & B), in striking
contrast to the 2C4G2 cell-derived tumor sections (C , H). Note
that rabbit mAb to GFP is highly specific. The inset in A was
enlarged as B; and the inset in C was enlarged as D, showing GFP-
positive RBCs. The pCSCs-derived RBCs appeared to be smaller
in size than host-derived GFP-negative RBCs (D, short green
arrows). The level of GFP expression in pCSC-derived TVECs
(C , H), RBCs (F & G: arrows indicate RBCs expressing little or
no GFP), and cancer cells (E & H) is variable.
Found at: doi:10.1371/journal.pone.0001652.s001 (13.38 MB
TIF)
Figure S2 The effect of angiogenic cytokines on pCSC
expansion in vitro The pCSCs (2C4 clone) were cultured for
3 days in 2.0 ml of R10F (1610
5 cells/well) in 24-well plates
supplemented with cytokine IL-3 (50 ng/ml), IL-4 (20 ng/ml), IL-
6 (50 ng/ml); IL-7 (100 ng/ml), IL-13 (50 ng/ml), GM-CSF
(40 ng/ml), or FL (200 ng/ml) alone or in combination (GM-
CSF+IL-4; FL+IL-13; or IL-3+IL-6), as described in Fig. 2.
Control cultures were absent from exogenous cytokines. The cells
were harvested and trypan blue-excluded viable cells were
counted. The data shown are from 3 independent experiments,
and the p values were derived from one-tailed Student-T test when
compared to control cultures.
Found at: doi:10.1371/journal.pone.0001652.s002 (0.22 MB TIF)
Figure S3 Quantitation of angiogenic gene expression of pCSCs
responding to hypoxia The results of Fig. 3D was quantitated
using software ImageJ (1.37V, NIH). b-actin transcripts were used
as internal control to normalize angiogenic gene expression. A,
Constitutive expression of angiogenic genes in pCSCs (2C4) 24 hrs
after cell splitting. B, Kinetics of angiogenic gene expression in
pCSCs (2C4) responding to hypoxia.
Found at: doi:10.1371/journal.pone.0001652.s003 (0.29 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0001652.s004 (0.09 MB
DOC)
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